Company Arcturus Therapeutics Ltd Nasdaq

Equities

IL0011280240

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Inactive Instrument

Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.

USD in Million	2022	Weight	2023	Weight	Delta
Nucleic Acid-focused Technology 100.0 %	206	100.0 %	167	100.0 %	-19.03%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	206	100.0 %	167	100.0 %	-19.03%

Managers	Title	Age	Since
Joseph Payne CEO	Chief Executive Officer	52	13-02-28
Andrew Sassine DFI	Director of Finance/CFO	59	19-08-31
Padmanabh Chivukula COO	Chief Operating Officer	45	12-12-31
Juergen Froehlich CTO	Chief Tech/Sci/R&D Officer	68	23-02-28
Neda Safarzadeh IRC	Investor Relations Contact	-	-
Lance Kurata LAW	General Counsel	54	20-08-09
Kevin T. Skol PRN	Corporate Officer/Principal	-	01-12-31

Members of the board	Title	Age	Since
Edward W. Holmes BRD	Director/Board Member	83	19-08-31
James F. Barlow BRD	Director/Board Member	65	18-05-26
Peter Farrell CHM	Chairman	81	18-05-26
Andrew Sassine DFI	Director of Finance/CFO	59	19-08-31
Magda Marquet BRD	Director/Board Member	65	18-05-26
Jing Marantz BRD	Director/Board Member	59	21-12-06
Joseph Payne CEO	Chief Executive Officer	52	13-02-28
John Markels BRD	Director/Board Member	58	22-12-07

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	26,915,243	24,560,665 ( 91.25 %)	0	91.25 %

Name	Equities	%	Valuation
Federated Global Investment Management Corp. 17.50 %	4,711,512	17.50 %	159 M $
BlackRock Advisors LLC 8.242 %	2,218,403	8.242 %	75 M $
ARK Investment Management LLC 6.278 %	1,689,649	6.278 %	57 M $
STATE STREET CORPORATION 6.055 %	1,629,666	6.055 %	55 M $
Joseph Payne 5.499 %	1,480,097	5.499 %	50 M $
Vanguard Fiduciary Trust Co. 5.418 %	1,458,380	5.418 %	49 M $
Nikko Asset Management Americas, Inc. 4.907 %	1,320,652	4.907 %	45 M $
Nikko Asset Management Americas, Inc. 4.907 %	1,320,652	4.907 %	45 M $
SUMITOMO MITSUI TRUST HOLDINGS, INC. 4.743 %	1,276,519	4.743 %	43 M $
Dimensional Fund Advisors LP 4.046 %	1,088,930	4.046 %	37 M $

Arcturus Therapeutics Holdings, Inc.

10628 Science Center Drive Suite 250

92121, San Diego

http://www.arcturusrx.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.77%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.24%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.12B
MEDPACE HOLDINGS, INC.	+30.56%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.35%	11B

Other Biotechnology & Medical Research